

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

☒ Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2002

☐ Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission file number 000-32877

PRO-PHARMACEUTICALS, INC.

(Exact name of small business issuer as specified in its charter)

Nevada 04-3562325
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)

189 Wells Avenue, Suite 200, Newton, Massachusetts 02459
(Address of principal executive offices)

(617) 559-0033
(Issuer's telephone number)

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the issuer filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.

Yes ☐ No ☐

NOT APPLICABLE

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: The total number of shares of common stock, par value \$0.001 per share, outstanding as of November 1, 2002 was 17,868,897.

Transitional Small Business Disclosure Format (Check one): Yes ☐ No ☒

TABLE OF CONTENTS

Part I -- FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	
	Condensed Balance Sheets	3
	Condensed Statements of Operations	4
	Condensed Statements of Cash Flows	5
	Notes to Condensed Financial Statements	6
Item 2.	Plan of Operation	10
Item 3.	Controls and Procedures	15

Part II -- OTHER INFORMATION

Item 1.	Legal Proceedings	16
---------	-------------------------	----

Item 2.	Changes in Securities	16
Item 3.	Defaults Upon Senior Securities	16
Item 4.	Submission of Matters to a Vote of Security Holders	16
Item 5	Other Information	16
Item 6.	Exhibits and Reports on Form 8-K	16

2

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PRO-PHARMACEUTICALS, INC.
(A Development Stage Company)

CONDENSED BALANCE SHEETS (Unaudited)

	September 30, 2002	December 31, 2001
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 1,275,477	\$ 1,491,172
Prepaid expenses and other current assets	10,478	80,769
Deferred convertible notes payable extension costs	41,437	--
	-----	-----
Total current assets	1,327,392	1,571,941
	-----	-----
PROPERTY AND EQUIPMENT, Net	165,815	111,540
PATENTS	76,892	56,115
DEPOSITS AND OTHER ASSETS	26,951	26,951
	-----	-----
Total assets	\$ 1,597,050	\$ 1,766,547
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable	\$ 229,333	\$ 236,223
Accrued expenses	68,776	96,676
Convertible notes payable	115,000	195,000
Accrued interest related to convertible notes payable	18,815	22,803
	-----	-----
Total current liabilities	431,924	550,702
STOCKHOLDERS' EQUITY:		
Common stock, \$0.001 par value; 100,000,000 shares authorized, --and 17,287,647 and 15,524,410 issued and outstanding at September 30, 2002 and December 31, 2001, respectively	17,287	15,524
Deferred compensation	(56,101)	(91,575)
Stock subscription receivable	(132,000)	--
Additional paid-in capital	8,052,413	5,450,106
Deficit accumulated during the development stage	(6,716,473)	(4,158,210)
	-----	-----
Total stockholders' equity	1,165,126	1,215,845
	-----	-----
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 1,597,050	\$ 1,766,547
	=====	=====

See notes to condensed financial statements.

PRO-PHARMACEUTICALS, INC.
(A Development Stage Company)

CONDENSED STATEMENTS OF OPERATIONS (Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,		Period From Inception (July 10, 2000) To September 30,
	2002	2001	2002	2001	2002
OPERATING EXPENSES:					
Research and development	\$ 316,592	\$ 334,435	\$ 1,077,304	\$ 489,976	\$ 2,071,011
General and administrative	322,430	301,337	1,120,387	903,989	2,475,721
	-----	-----	-----	-----	-----
Total operating expenses	(639,022)	(635,772)	(2,197,691)	(1,393,965)	(4,546,732)
INTEREST INCOME	3,726	4,326	15,683	16,992	40,861
INTEREST EXPENSE	(28,264)	(557,864)	(376,255)	(1,816,348)	(2,207,247)
	-----	-----	-----	-----	-----
Net loss	\$ (663,560)	\$ (1,189,310)	\$ (2,558,263)	\$ (3,193,321)	\$ (6,713,118)
	-----	-----	-----	-----	-----
NET LOSS PER SHARE - BASIC AND DILUTED	\$ (0.04)	\$ (0.09)	\$ (0.16)	\$ (0.24)	
	-----	-----	-----	-----	
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING -					
Basic and diluted	15,990,355	13,883,404	15,726,838	13,072,422	
	-----	-----	-----	-----	

See notes to condensed financial statements.

4

PRO-PHARMACEUTICALS, INC.

(A Development Stage Company)

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

	Nine Months Ended September 30,		Period From Inception (July 10, 2000) To September 30,
	2002	2001	2002
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net loss	\$ (2,558,263)	\$ (3,193,321)	(6,713,118)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation	29,691	2,572	41,847
Stock based compensation expense	65,364	--	212,681
Non cash interest expense on convertible notes payable	139,447	1,231,357	1,397,459
Expense related to issuance of warrants to purchase common stock	235,987	--	235,987
Writeoff of intangible assets	--	--	107,000
Debt conversion expense	--	503,019	503,019
Changes in current assets and liabilities:			
Prepaid and other expenses	70,290	(24,160)	(10,479)
Deposits	--	(26,951)	(26,951)
Accounts payable	(6,890)	211,188	229,333
Accrued expenses	(27,900)	256,112	58,776
Accrued interest related to convertible notes payable	(3,988)	--	18,815
	-----	-----	-----
Net cash used in operating activities	(2,056,262)	(1,040,184)	(3,945,631)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Purchases of property and equipment	(83,966)	(96,800)	(207,662)
Increase in patents costs and other assets	(20,777)	(38,650)	(76,892)
	-----	-----	-----

Net cash used in investing activities	(104,743)	(135,450)	(284,554)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Net proceeds from sale of common stock	1,925,310	--	1,934,310
Return of placement fee	20,000	--	20,000
Proceeds from sale of common stock and warrants	--	809,700	2,229,750
Net proceeds from convertible notes payable	--	1,026,102	1,320,602
Cash received from stock subscription receivable	--	1,000	1,000
	-----	-----	-----
Net cash provided by financing activities	1,945,310	1,836,802	5,505,662
	-----	-----	-----
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(215,695)	661,168	1,275,477
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,491,172	204,745	--
	-----	-----	-----
CASH AND CASH EQUIVALENTS, END OF PERIOD	\$ 1,275,477	\$ 865,913	\$ 1,275,477
	=====	=====	=====
NONCASH FINANCING ACTIVITIES			
Conversion of convertible notes and accrued interest to common stock	\$ 90,257	\$ 1,185,733	\$ 1,306,116

See notes to condensed financial statements.

PRO-PHARMACEUTICALS, INC.
(A Development Stage Company)

NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited)
September 30, 2002

1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

Pro-Pharmaceuticals, Inc. (the Company) was established in July 2000. The Company is in the development stage and is engaged in developing technology that will reduce toxicity and improve the efficacy of currently existing chemotherapy drugs by combining the drugs with a number of specific carbohydrate compounds. The carbohydrate-based drug delivery system may also have applications for drugs now used to treat other diseases and chronic health conditions.

The Company is devoting substantially all of its efforts toward product research and development and raising capital. Its product candidates are still in the research and development stage, with one approved to commence clinical trials. The Company is subject to a number of risks similar to those of other development-stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. To date, the Company has raised capital principally through the issuance of convertible notes and the sale of \$0.001 par value common stock through private placements.

As of September 30, 2002, the Company had \$1,275,477 in cash and working capital of \$895,468. The Company began a private placement of common stock in September 2002 and had raised \$2,093,360 as of November 1, 2002, of which \$1,483,360 was raised during the three months ended September 30, 2002.

The Company's financial statements have been presented on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is in the development stage, has incurred a net loss since inception of \$6,713,118 and expects to incur additional losses in the near future. These factors raise substantial doubt about the Company's ability to continue as going concern. Successful

completion of the Company's development program and, ultimately, the attainment of profitable operations is dependent upon future events, including maintaining adequate financing to fulfill its development activities and eventual sales of product adequate to support the Company's cost structure. The Company is actively seeking additional financing to fund future operations and future significant investments in the business. However, there can be no assurance that the Company will be able to obtain financing.

BASIS OF PRESENTATION

The condensed financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements should be read in conjunction

6

with the financial statements and the notes thereto included in the Company's latest annual report on Form 10-KSB.

The condensed financial statements, in the opinion of management, include all adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company's financial position and the results of operations. These results are not necessarily indicative of the results to be expected for the entire year.

SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies followed by the Company in preparing its financial statements are set forth in Note 1 to the financial statements included in its Form 10-KSB for the year ended December 31, 2001. The Company has made no changes to these policies during this quarter.

2. NET LOSS PER SHARE

Basic and diluted net loss per share is presented in conformity with Statement of Financial Accounting Standards (SFAS) No. 128, Earnings per Share, for all periods presented. In accordance with SFAS No. 128, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period, less shares subject to repurchase. Diluted weighted-average shares are the same as basic weighted-average shares since the inclusion of 1,933,731 and 2,078,091 shares issuable pursuant to the exercise of stock options and warrants and conversion of convertible debt as of September 30, 2002 and September 30, 2001, respectively, would have been antidilutive.

3. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	September 30, 2002	December 31, 2001
	-----	-----
Property and equipment:		
Computer and office equipment	\$ 62,583	\$ 56,681
Furniture and fixtures	41,317	39,746
Leasehold improvements	103,762	27,269
	-----	-----
Total	207,662	123,696
Less accumulated depreciation	(41,847)	(12,156)
	-----	-----
Property and equipment - net	\$ 165,815	\$ 111,540
	=====	=====

4. CONVERTIBLE NOTES PAYABLE

On May 9, 2002, the Company extended for one year the holders' right to convert \$195,000 of notes payable to common stock extending the maturity dates to the first quarter of 2003. In consideration for the extension, the holders were entitled to receive one-quarter of one share of the Company's common stock for each whole dollar amount of principal, or 48,750 shares of common stock. During the second quarter, the Company deferred \$170,625 in costs associated with the

extension, based on the fair value of the Company's common stock of \$3.50 per share. These deferred convertible notes payable costs will be amortized ratably over the twelve month extended term of the notes, if the notes are held to maturity, or expensed immediately upon conversion.

The Company issued 20,000 of these shares during the period ended June 30, 2002, and the remaining 28,750 in the quarter ended September 30, 2002. In June 2002, \$80,000 principal amount of convertible notes payable and \$5,128 in related interest was converted into 45,128 shares of common stock. In addition, \$70,000 in deferred convertible notes payable extension costs was expensed immediately upon conversion. In October 2002, the Company settled a convertible note payable of \$100,000 by repaying \$86,000, converting the remaining \$14,000 in principal into 7,000 shares of common stock pursuant to the original terms of the note agreement, and paying accrued interest in the amount of \$17,051.

5. EQUITY OFFERINGS

On December 13, 2001, the Company commenced a public offering of 1,428,572 shares of common stock at a price to the public of \$3.50 per share. The Company concluded the offering on June 11, 2002. The Company sold 185,999 shares of common stock under this offering, for gross proceeds of \$650,998, all in 2002.

In August 2002, the Company began a private placement of units of Series A preferred stock and warrants to purchase common stock, exempt from registration pursuant to Rule 506 of Regulation D under the Securities Act of 1933, in order to raise up to \$6,588,400 to cover its expenditures. The Company did not sell any securities under this offering and has discontinued it.

In September 2002, the Company began a private placement of up to 10 million shares of common stock at \$1.00 per share, exempt from registration pursuant to Rule 506 of Regulation D under the Securities Act of 1933. During the quarter ended September 30, 2002, the Company sold 1,483,360 shares under this offering for gross proceeds of \$1,483,360. Subsequent to quarter end, through November 1, 2002, the Company sold an additional 610,000 shares at \$1.00 per share for additional gross proceeds of \$610,000. The Company agreed to compensate a registered investment adviser with respect to shares purchased by its clients based on the recommendation of the adviser. As of September 30, 2002, the adviser was entitled to receive 89,000 shares of common stock.

6. OPTIONS AND WARRANTS

Commencing as of March 1, 2002, under an agreement with a shareholder who is also a board member, the Company compensates the shareholder for consulting services rendered by making monthly grants to the shareholder of options to purchase 2,000 shares of common stock. The options are granted on the first day of the month following the month of service, vest immediately and expire in 10 years. In accordance with this agreement, options to purchase 2,000, 6,000 and 6,000 shares were granted during the three-month periods ended March 31, 2002, June 30, 2002, and September 30, 2002, respectively. These options were valued by the Company at \$4,291, \$12,873, and \$12,726 respectively, or approximately \$2.14 per share. The fair value of these options was estimated at the date of grant using a Black-Scholes option pricing model, based on the following assumptions: a risk free interest rate range of 2.3 to 3.9%, a volatility factor of 95%, a dividend rate of 0.0%, and a weighted-average expected life of three years. The options were recognized as a general and administrative expense in the statement of operations for the applicable period.

The Company had previously incurred a liability of approximately \$50,000 to finders in connection with its 2001 debt offering. In the first quarter of 2002, in response to certain liquidity issues, the Company settled this liability through the issuance of warrants to purchase 110,000 shares of common stock. The warrants are exercisable immediately, have an exercise price of \$3.50

per share and a 10 year life. These warrants were valued by the Company at \$235,987, and the

8

excess value of the warrants over the liability was recorded as interest expense in the statement of operations for the period ended March 31, 2002.

7. RECENT ACCOUNTING PRONOUNCEMENTS

On January 1, 2002, the Company adopted SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, which addresses financial reporting for the impairment or disposal of long-lived assets. SFAS 144 supersedes SFAS 121 and the accounting and reporting provisions of APB 30 related to the disposal of a segment of a business. The adoption of this statement did not have a significant effect on the Company's financial position or results of operations.

9

Item 2. Plan of Operation

This quarterly report on Form 10-QSB contains, in addition to historical information, forward-looking statements. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our potential products; uncertainties associated with preclinical and clinical trials of our drug delivery candidates; our lack of experience in product development and expected dependence on potential licensees and collaborators for commercial manufacturing, sales, distribution and marketing of our potential products; possible development by competitors of competing products and technologies; lack of assurance regarding patent and other protection of our proprietary technology; compliance with and change of government regulation of our activities, facilities and personnel; uncertainties as to the extent of reimbursement for our potential products by government and private health insurers; our dependence on key personnel; our history of operating losses and accumulated deficit; and economic conditions related to the biotechnology and biopharmaceutical industry, each as discussed in our Annual Report on Form 10-KSB for the year ended December 31, 2001, filed with the Securities and Exchange Commission. We cannot assure you that we have identified all the factors that create uncertainties. Readers should not place undue reliance on forward-looking statements.

Overview

We are currently in the development stage and have not yet generated any operating revenues. Since our formation in July 2000, we have been engaged in research and development activities in connection with identifying and developing a biochemical technology that will reduce toxicity and improve the efficacy of currently-used drug therapies, including cancer chemotherapies, by combining the drugs with a number of carbohydrate compounds. We have identified polysaccharides that could be utilized as a potential drug delivery system. Polysaccharides are molecules consisting of one or more types of sugars.

Research and Development

Our drug development program is focused on novel drug delivery platforms to upgrade the efficacy and reduce the toxicity of some of the proven, commonly used anti-cancer drugs. We believe we can enhance the delivery of the chemotherapeutic drugs by utilizing sugar-specific receptors found on cancer cells. Our studies indicate that a polysaccharide with a suitable chemical structure, in combination with a chemotherapy drug, would increase cellular membrane fluidity and permeability, thereby assisting delivery of the drug.

The first group of drugs selected to go through our "upgrade programs" are 5-Fluorouracil, Adriamycin, Taxol, Cytosan and Cisplatin. The two patent-pending, drug delivery platforms, which we have identified and

trademarked, are as follows:

- o DAVANAT(TM): A galactomannan derivative, which is a formulation using oligomeric carbohydrates as the target vehicle for chemotherapeutic drugs.
- o UCLT(TM): UNIVERSAL CARBOHYDRATE LINKAGE TECHNOLOGY(TM), (UCLT(TM)) enhances the delivery of chemotherapeutic drugs by utilizing carbohydrate specific receptors found on cancer cells.

10

DAVANAT(TM)-1

DAVANAT(TM) combined with 5-fluorouracil (5-FU), referred to as DAVANAT(TM)-1 is our first drug combination that is advancing to human clinical trials. DAVANAT(TM) was selected using animal models as the most promising combination for 5-FU. Earlier this year, DAVANAT(TM)-1 was submitted to the FDA and was approved as an investigational new drug application (IND), which authorizes us to begin human clinical trials. We anticipate that human clinical trials will start in December 2002. All of our pre-clinical studies are conducted at independent accredited laboratories.

Toxicity Studies

Our initial toxicity studies in smaller animals, conducted in early 2001, were performed to test the potential reduction of toxicity of anticancer drugs in combination with certain of our polysaccharide compounds. Results of one study demonstrated that one of our polysaccharide compounds, DAVANAT(TM), might significantly decrease the toxicity of 5-FU. A second, similar study was performed to test a potential reduction of toxicity of Adriamycin in combination with each of two selected polysaccharide compounds. Results indicated that DAVANAT(TM) might decrease the toxicity of Adriamycin. The fact that two different cancer drugs with chemically unrelated structures showed a marked reduction of their toxicity in combination with DAVANAT(TM) indicates that there might be some fundamental underlying biological reasons related to this polysaccharide, rather than to the drugs, for the reduction in toxicity. For further information about these studies, please refer to our Quarterly Report on Form 10-QSB for the quarter ended March 31, 2002, filed with the Securities and Exchange Commission.

In subsequent pre-clinical experiments conducted in 2001 and 2002, we studied on larger animals the toxicity reduction of DAVANAT(TM)-1, a DAVANAT(TM) combination with 5-FU, which had demonstrated toxicity reduction in the prior studies. These experiments were performed in accordance with FDA guidelines and recommendations on rats (acute and long-term toxicity study) and dogs (acute and long-term toxicity study) measuring the effect of the DAVANAT(TM)/5-FU combination on blood structure and survival of these animals. Preliminary results indicate that the DAVANAT(TM)/5-FU combination decreased toxicity, resulting in lower animal mortality and decreased loss of blood structure components in comparison to the results in animals which were administered 5-FU alone. These studies were presented to the FDA as part of our IND submission.

We are presently conducting additional toxicity studies on rats using escalating dosages of DAVANAT(TM) in support of our Phase I program.

Efficacy Studies

We undertook independent studies at Southern Research Institute and Charles River Laboratories to test a potential change in the therapeutic efficacy of DAVANAT(TM) in a combination with 5-FU, which had decreased toxicity of the drug in healthy animals. Results of the studies demonstrated that DAVANAT(TM), might also increase efficacy of 5-FU when administered into cancer-carrying animals. The studies, conducted with two different human colon tumors implanted into the test animals, demonstrated a decrease in tumor size following administration of 5-FU alone, as well as a significant decrease with the administration of the DAVANAT(TM)/5-FU combination.

11

Two of our efficacy studies were conducted to evaluate the compatibility

of DAVANAT(TM) with leucovorin, which is commonly used in cancer treatment with 5-FU. The studies showed that DAVANAT(TM) and leucovorin do not interfere with each other when administered following standard procedure, and that the DAVANAT(TM)/5-FU combination is superior, compared to 5-FU/leucovorin when both are administered in tumor-bearing animals. Leucovorin is a folinic acid derivative, which may enhance both the therapeutic and toxic effect of 5-FU in cancer therapy. In these studies, the growth of the tumor was decreased significantly by using a DAVANAT(TM)/5-FU combination compared to 5-FU.

We also conducted a study that involved injecting radiolabeled DAVANAT(TM) (with and without 5-FU) into tumor-free and tumor-bearing animals. The study provided extensive experimental data with respect to DAVANAT(TM) distribution in organs and tissues (liver, kidney, lungs, plasma, and tumor) and the capacity of such organs and tissue to clear DAVANAT(TM) after various time periods. The study indicated that DAVANAT(TM) may protect the liver from a toxic effect of 5-FU yet increase the amount, and hence the therapeutic effect, of 5-FU in the tumor. In other words, we have indications that DAVANAT(TM) may decrease toxicity and increase efficacy of 5-FU.

In addition to DAVANAT(TM)-1, we are also conducting pre-clinical studies for Adriamycin and Taxol, both in combination with DAVANAT(TM) and other polysaccharide compounds.

Although the foregoing studies are encouraging, the results achieved in preclinical studies with animals are often not duplicated in human patients. Please see "Risk Factors that May Affect Results -- Our product candidates will be based on novel technologies" in our 2001 Form 10-KSB.

Phase I Clinical Trials in Humans

We submitted an investigational new drug application to the FDA on May 26, 2002 based on the pre-clinical data obtained from our 5-FU studies. Following discussions with the FDA, the application was accepted as of June 26, 2002 which authorized us to begin Phase I clinical trials with humans. In Phase I we will evaluate the ability of cancer patients to tolerate increasing doses of DAVANAT(TM) while receiving a stable dose of 5-FU for treatment of colorectal cancer. The Phase I study has two primary objectives: (1) to determine the maximum dose of DAVANAT(TM) that can be tolerated when administered with a stable dose of 5-FU, and (2) to define the dose-limiting toxicities of DAVANAT(TM) in combination with 5-FU. We expect that up to 40 male and female patients suffering from metastatic cancer, who failed the first line chemotherapy treatment, to participate in the study. We are currently selecting sites and conducting other planning activities for Phase I clinical trials. The pharmaceutical company with which we contracted to produce DAVANAT(TM), a certified GMP facility, has manufactured sufficient quantities for the doses that will be needed for the forthcoming human clinical trials.

We are engaging an independent contract research organization to undertake the clinical trials on our behalf. We have engaged a professional consultant to serve as medical director of our clinical trials.

UCLT(TM)

As detailed above, we are currently developing a variety of formulations of carbohydrates chemically linked to anti-cancer drugs. We have chemically synthesized a few novel products that are carbohydrate derivatives of Adriamycin, and have conducted pre-clinical animal experiments, studying both toxicity (on healthy animals) and efficacy (on cancer-carrying animals). Preliminary results of these experiments indicate that all of the synthesized carbohydrate-Adriamycin compounds, and particularly one, named Galactomycin, were significantly less toxic compared to

the original Adriamycin, and demonstrate therapeutic efficacy as well. In the case of Galactomycin, the preliminary results, compared to control animals, indicated a therapeutic efficacy more than twice as high as that for the parent Adriamycin, particularly with repeated administrations. Unlike repeated injections of Adriamycin, which result in a cumulative toxic effect, Galactomycin, at repeated injections, apparently increases its therapeutic effect while retaining low toxicity.

We have three regular utility patent applications pending in the United States. The patent applications cover methods and compositions for reducing side effects in chemotherapeutic formulations, and improving efficacy and reducing toxicity of chemotherapeutic agents. In addition, international patent applications corresponding to two of our U.S. applications have been filed under the Patent Cooperation Treaty.

We filed with the U.S. Patent and Trademark Office (PTO) applications to register the following trademarks/service marks: ADVANCING DRUGS THROUGH GLYCOSCIENCE; GLYCO-UPGRADE; PRO-PHARMACEUTICALS, INC.; DAVANAT; UCLT; UNIVERSAL CARBOHYDRATE LINKER TECHNOLOGY and CARBOSOME. In February 2002, the PTO issued Notices of Allowance for the marks ADVANCING DRUGS THROUGH GLYCOSCIENCE and GLYCO-UPGRADE; in March 2002 the PTO issued a Notice of Allowance for the mark PRO-PHARMACEUTICALS, INC.; in October 2002, the PTO issued a Notice of Allowance for the mark DAVANAT and the mark UCLT was published in the PTO's Official Gazette; and in November 2002, UNIVERSAL CARBOHYDRATE LINKER TECHNOLOGY was published in the Official Gazette. If no objection to the marks UCLT or UNIVERSAL CARBOHYDRATE LINKER TECHNOLOGY are timely filed, Notices of Allowance will issue for the marks in due course. We filed for extensions of time to provide evidence of use for the marks ADVANCING DRUGS THROUGH GLYCOSCIENCE and GLYCO-UPGRADE, and the PTO has issued approvals for both extensions. In order to obtain registrations for these marks, the next deadline for filing evidence of use or requests for extension of time to file evidence of use is February 5, 2003. We filed for an extension of time to provide evidence of use for the mark PRO-PHARMACEUTICALS, and the PTO has issued an approval for this extension. In order to obtain a registration for this mark, the next deadline for filing evidence of use or a request for extension of time to file evidence of use is March 26, 2003. In order to obtain a registration for DAVANAT, we must file evidence of use or file for an extension of time to provide evidence of use by April 22, 2003.

Plan of Operation

As discussed in our 2001 Form 10-KSB, our Massachusetts predecessor corporation was established in July 2000. Our present corporation was incorporated in Nevada in January 2001 for the purpose of effecting a business combination with the Massachusetts predecessor. The transaction included a merger in which we are the surviving corporation. We are a development-stage company and have not generated any revenues to date. Our common stock commenced to

trade on the Over-the-Counter Bulletin Board in September 2002. In connection with the start of public trading of our common stock, we hired a Vice President of Investor Relations.

In August 2002, we began a private placement of units of Series A preferred stock and warrants to purchase Common Stock, exempt from registration pursuant to Rule 506 of Regulation D under the Securities Act of 1933 in order to raise up to \$6,588,400 to cover our expenditures. We did not sell any securities under this offering and have discontinued it.

In September 2002, we began a private placement of up to 10 million shares of common stock at \$1.00 per share, exempt from registration pursuant to Rule 506 of Regulation D under the Securities Act of 1933. During the quarter ended September 30, 2002, we sold 1,483,360 shares under this offering for gross proceeds of \$1,483,360. Subsequent to quarter end, through November 1, 2002, we sold an additional 610,000 shares at \$1.00 per share for additional gross proceeds of \$610,000.

As of September 30, 2002, we had \$1,275,477 in cash and working capital of \$895,468. We intend to dedicate the proceeds of our September 2002 private placement to research and development, including expenses of Phase I/II clinical trials of our drug candidate for which the FDA approved our investigational new drug application, and general and administrative expenses.

With the capital we have raised to date, and the additional capital that we are attempting to raise under the private placement of our common stock discussed above, we believe that we will be able to proceed with our current plan of operations and meet our obligations for approximately the next twelve months. If we do not raise the additional funds, we would reduce our research

and development expenditures. However, since we outsource most of our research and development activities, our business structure is flexible, enabling us to slow or halt our activities and still remain viable until adequate funding becomes available.

Our financial statements have been presented on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We are in the development stage, have incurred a net loss since inception of \$6,713,118 and expect to incur additional losses in the near future. These factors raise substantial doubt about our ability to continue as a going concern. Successful completion of our development program and, ultimately, the attainment of profitable operations is dependent upon future events, including maintaining adequate financing to fulfill our development activities and achieving a level of sales adequate to support our cost structure. We are actively seeking additional financing to fund future operations and future significant investments in the business. However, there can be no assurance that we will be able to obtain financing.

During the next twelve months, we anticipate that our research and development activities will include commencement of a Phase I first-in-man clinical trial as discussed above under " -- Research and Development -- Phase I Clinical Trials in Humans," as well as continuing preclinical animal experiments to study toxicity and efficacy of 5-FU and other cancer chemotherapies both in combination with our polysaccharide compounds and, in the case of Adriamycin, as chemically modified with sugar residues via "linkers" of a certain chemical structure that are our proprietary technology.

We do not anticipate building in-house research or development facilities, or hiring staff to conduct those activities. Consequently, we do not expect to make any purchases or sales of plant or significant equipment during the next twelve months. We currently have seven employees, all full-time. We do not expect to make significant additions to our employee headcount.

14

Item 3. Controls and Procedures

(a) Evaluation of disclosure controls and procedures. Based on his evaluation as of a date within 90 days prior to the filing date of this Quarterly Report on Form 10-QSB, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934) are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

(b) Changes in internal controls. There were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

15

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None

Item 2. Changes in Securities

In September 2002, we began a private placement of up to 10 million shares of common stock at \$1.00 per share, exempt from registration pursuant to Rule 506 of Regulation D under the Securities Act of 1933. During the quarter ended September 30, 2002, we sold 1,483,360 shares under this offering for gross proceeds of \$1,483,360. Subsequent to quarter end, through November 1, 2002, we sold an additional 610,000 shares at \$1.00 per share for additional gross proceeds of \$610,000. We agreed to compensate a registered investment adviser with respect to shares purchased by its clients based on the recommendation of the adviser. As of November 1, 2002, the adviser is entitled to receive 154,000

shares of common stock.

Item 3. Defaults Upon Senior Securities

None

Item 4. Submission of Matters to a Vote of Security Holders

None

Item 5. Other Information

Dr. Mildred Christian, a member of our Scientific Advisory Board, was elected to our Board of Directors effective October 1, 2002. Dr. Christian, an experienced toxicologist, and founder and executive with research laboratories, has participated in hundreds of developmental ("teratology"), reproductive and general toxicology evaluations.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

The Exhibits filed as part of this Form 10-QSB are listed on the Exhibit Index immediately preceding such Exhibits, which Exhibit Index is incorporated herein by reference.

(b) Reports on Form 8-K

We filed a report on Form 8-K with the SEC, pursuant to Item 5, on September 5, 2002, as amended and filed with the SEC as Form 8-K/A on September 18, 2002, concerning termination of a private placement offering and commencement of a new private placement offering.

16

SIGNATURE

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 14, 2002.

PRO-PHARMACEUTICALS, INC.
Registrant

By: /S/ DAVID PLATT

Name: David Platt
Title: President, Chief Executive
Officer, Treasurer and
Secretary (Principal
Executive Officer and
Principal Financial and
Accounting Officer)

17

CERTIFICATION

I, David Platt, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Pro-Pharmaceuticals, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial

information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Dated: November 14, 2002

/S/ DAVID PLATT

Name: David Platt
Title: President, Chief Executive
Officer, Treasurer and Secretary
(Principal Executive Officer)

18

CERTIFICATION

I, David Platt, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Pro-Pharmaceuticals, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a) designed such disclosure controls and procedures to ensure that

material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Dated: November 14, 2002

/S/ DAVID PLATT

Name: David Platt
Title: President, Chief Executive
Officer, Treasurer and Secretary
(Principal Financial and
Accounting Officer)

19

EXHIBIT INDEX

Exhibit

Number	Description of Document	
3.1	Articles of Incorporation of the Registrant, dated January 26, 2001	*
3.2	Amended and Restated By-laws of the Registrant	**
10.1	Assignment and Assumption Agreement, dated April 23, 2001, by and between Developed Technology Resource, Inc. and DTR-Med Pharma Corp.	*
10.2	Stock Exchange Agreement, dated April 25, 2001, by and among Developed Technology Resource, Inc., DTR-Med Pharma Corp., Pro-Pharmaceuticals, Inc. (Massachusetts) and the Shareholders (as defined therein)	*
10.3	Pro-Pharmaceuticals, Inc. 2001 Stock Incentive Plan	**
16	Letter from Scillia Dowling & Natarelli LLC to the Commission, dated February 25, 2002, concerning change in certifying accountant	***
21	Subsidiaries of the Registrant	None
99.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	
99.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	

* Incorporated by reference to the Registrant's Registration Statement on Form 10-SB, as filed with the Commission on June 13, 2001.

- ** Incorporated by reference to the Registrant's Quarterly Report on Form 10-QSB for the period ended September 30, 2001, as filed with the Commission on November 14, 2001.
- *** Incorporated by reference to the Registrant's Current Report on Form 8-K as filed with the Commission on February 25, 2002.

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Pro-Pharmaceuticals, Inc. (the "Company") on Form 10-QSB for the period ended September 30, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned officer of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /S/ DAVID PLATT

Name: David Platt
Title: President, Chief Executive
Officer, Treasurer and Secretary
(Principal Executive Officer)

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Pro-Pharmaceuticals, Inc. (the "Company") on Form 10-QSB for the period ended September 30, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned officer of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /S/ DAVID PLATT

Name: David Platt
Title: President, Chief Executive
Officer, Treasurer and Secretary
(Principal Financial and
Accounting Officer)